NMR-BIO's new project, Alp'Helix, aims to carry out a feasibility study to develop MaxLZ, a future anti-cancer drug targeting the c-Myc protein involved in 70% of cancers. This molecule will be optimized to offer the best possible cell penetration, stability and selectivity properties, with the aim of improving patients' quality of life.

​​

For more infomation please consult ALP'HELIX website.